# Biorce

> Biorce is a Barcelona-based healthtech company building AI-native infrastructure for clinical trials. Its core product, Aika, helps pharmaceutical companies, biotechs and CROs design regulator-ready trial protocols in roughly 90 seconds, drawing on a corpus of more than one million clinical studies and 260,000+ protocols. By cutting protocol design time by at least 50% and flagging regulatory and feasibility risks early, Biorce aims to compress the years and billions of dollars it takes to bring a drug to market - so treatments reach patients sooner. In February 2026 it closed a USD $52.5M Series A led by DST Global, the largest Series A to date in the Iberian healthtech and AI ecosystem.

- **Founded:** 2022
- **Headquarters:** Barcelona, Spain
- **Founders:** Pedro Coelho (Founder & CEO), Clara Bernardes (Co-founder, Head of Clinical / Chief Scientific Officer), Jose Faria (Co-founder, Head of Engineering), Diogo Pisoeiro (Co-founder, Head of Product Design)
- **Team size:** ~130 employees (international team across Europe and the US; reported ~45% female)
- **Products:** Aika, Jarvis, Track Impact, Defensible AI, ROI Calculator
- **Notable:** Closed a USD $52.5M Series A in February 2026 - the largest Series A to date in the Iberian healthtech and AI ecosystem., Total funding surpassed $60M within roughly two years of founding., Won the Health Tech category at the 4YFN26 Awards (Best of Show).

## Products & services

- **Aika** — Biorce's AI engine for clinical trial design. It combines machine learning, statistical modeling and natural language processing, trained on 1M+ clinical studies and 260,000+ protocols, to generate regulator-ready trial protocols in roughly 90 seconds, simulate trial models, flag feasibility and regulatory risks, and cut protocol design time by at least 50%.
- **Jarvis** — An earlier Clinical AI assistant providing universal access to clinical data, helping research teams query and reason over clinical evidence.
- **Track Impact** — Operational tracking that monitors trial performance and the downstream impact of protocol decisions.
- **Defensible AI** — Explainable AI layer that produces evidence-based, auditable recommendations aligned with FDA and EMA expectations, so trial sponsors can defend design choices to regulators.
- **ROI Calculator** — Tool that estimates the cost and time savings of optimizing a clinical trial's design with Biorce.

## Achievements

- Closed a USD $52.5M Series A in February 2026 - the largest Series A to date in the Iberian healthtech and AI ecosystem.
- Total funding surpassed $60M within roughly two years of founding.
- Won the Health Tech category at the 4YFN26 Awards (Best of Show).
- Built Aika on a data foundation of 1M+ clinical studies and 260,000+ protocols, generating regulator-ready protocols in ~90 seconds at a reported 86% accuracy.
- Ended 2025 approximately 200% above its revenue target.
- Attracted angel backing from Revolut CEO Nik Storonsky and Mistral AI CEO Arthur Mensch.

## Latest updates

- **2026-02** — Closed USD $52.5M Series A led by DST Global; largest Series A in Iberian healthtech/AI to date.
- **2026-02** — Won the Health Tech category at the 4YFN26 Awards in Barcelona.
- **2026-03** — Announced opening of an Austin, Texas office and relocation of C-level team to support US expansion.
- **2026-05** — Hosted a clinical-trials conference in Boston as part of US market entry.
- **2025-07** — Raised EUR 5M from Norrsken VC to expand the Aika platform.

## Links

- Website: https://biorce.com
- LinkedIn: https://www.linkedin.com/company/biorce
- Instagram: https://www.instagram.com/wearebiorce/

---

Profile page: https://yespress.io/biorce
Published by YesPress — https://yespress.io
Last updated: 2026-06-16